酒精性肝硬化患者血清肿瘤坏死因子受体的检测及其临床意义

Detection and Significance of Serum Tumor Necrosis Factor Receptors in Patients with Alcoholic Liver Cirrhosis

同特异性免疫测定ELISA法检测了32例酒精性肝硬化患者和10名健康人血清中肿瘤坏死因子受体的水平。酒精性肝硬化患者两种可溶性肿瘤坏死因子受体(P55、P75)均明显高于健康组(P<0.01),肝硬化代偿期与失代偿期患者比较有显著差异(P值分别<0.005,<0.01)。这些结果提示循环中可溶性肿瘤坏死因子受体(STNFR)的水平与肝硬化和疾病的进展程度呈正相关。

Tumor necrosis factor alpha (TNFα) is an important mediator of various inflammatory and immune responses. The multiple biological activites of TNFαare mediated by two distinct cell surface receptors of 55 kD (TNFR p55) and 75kD (TNFR p75). Soluble tumor necrosis factor receptors (STNFR p55, STNFR p75) are naturally occurring substance which can inhibit the biological effects of TNFα. We used specific immunoassays (ELISA) to detect circulating TNFR including their levels in serum of 32 patients with alcoholic liver cirrhosis (ALC) and 10 healthy subjects. The mean concentrations of both the soluble type p55 and p75 receptors were significantly higher in the ALC than in the healthy controls (P<0.01). The mean levels of both types p55 and p75 in compensated ALC were significantly different than in decompensated ALC (P<0. 005 and P<0. 01 respectively). The results suggest that circulating levels of the STNFR were positively correlated with ALC and ongoing disease activity.